Insmed INC Form 4 insider transactions

Roger Adsett, Chief Operating Officer of INSMED Inc, sold 239,850 shares of common stock on August 10, 2026 for $133.27 per share.

Martina M.D. Flammer, Chief Medical Officer of INSMED Inc, sold 27,173 shares of common stock on August 6, 2026.

William Lewis, Chair and CEO and a Director of INSMED Inc, sold 10,700 shares of common stock on July 23, 2026.

Insmed Inc. reports that CEO William Lewis sold a total of 10,699 shares of common stock on July 9, 2026, through a pre-arranged 10b5-1 trading plan.

Martina Flammer, Chief Medical Officer of INSMED Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged 10b5-1 trading plan.

Insmed Inc. CEO William Lewis reported the sale of company stock valued at over $1.5 million, executed through a pre-arranged 10b5-1 trading plan.

Michael Alexander Smith, Chief Legal Officer of INSMED Inc., reported a sale of 1,806 shares of common stock for $95.82 per share, executed under a pre-arranged 10b5-1 trading plan.

Insmed Inc. Director William Lewis reported a sale of 6,515 common shares for $94.03 per share, executed under a pre-arranged 10b5-1 trading plan.

Insmed Incorporated Chief Operating Officer Roger Adsett sold 2,370 shares of common stock to cover tax withholding obligations.

Insmed Chief Financial Officer Sara Bonstein sold 2,404 shares of common stock to cover tax obligations related to RSU vesting.

Insmed Incorporated Chief Legal Officer Michael Smith sold 2,159 shares of common stock to satisfy tax obligations.

Insmed Chair and CEO William Lewis sold 7,605 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Insmed Chief Medical Officer Martina Flammer sold 4,424 shares of common stock to cover tax obligations and via a 10b5-1 plan.

Insmed Incorporated Chief Legal Officer Michael Smith sold 6,149 shares of common stock via a pre-arranged 10b5-1 trading plan.

William Lewis, Director and CEO of Insmed Inc., reported the sale of common stock valued at over $1.1 million through a pre-arranged 10b5-1 trading plan.

Insmed Chief Financial Officer Sara Bonstein sold 8,272 shares of common stock to cover tax obligations related to RSU vesting.

Insmed Incorporated director Carol Schafer was granted 3,305 restricted stock units as part of standard equity compensation.

Insmed Incorporated Chief Operating Officer Roger Adsett sold 5,837 shares of common stock to cover tax obligations.

Insmed Incorporated Director Melvin Sharoky was granted 3,305 restricted stock units as part of his annual director compensation.

Insmed Inc. director David R. Brennan was granted 3,305 restricted stock units as part of his annual compensation.

Insmed Incorporated director Clarissa Desjardins was granted 3,305 restricted stock units as part of her board compensation.

Insmed Incorporated director Leo Lee was granted 3,305 restricted stock units as part of his annual compensation.

INSMED's Chief Medical Officer, Martina M.D. Flammer, exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Insmed Inc. Director William Lewis reported the sale of common stock under a pre-arranged 10b5-1 trading plan.

Insmed Chair and CEO William Lewis exercised stock options and sold shares under a pre-established 10b5-1 trading plan.

William Lewis, Director and CEO of Insmed Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged 10b5-1 trading plan.

Insmed Inc. Chief Operating Officer Roger Adsett reported the sale of company stock totaling over 78,000 shares, executed under a pre-arranged trading plan.

INSMED's Chief Legal Officer, Michael Alexander Smith, completed a pre-scheduled sale of company stock following the exercise of options under a 10b5-1 plan.

INSMED Inc.'s Chair and CEO, William Lewis, executed a series of option exercises and subsequent sales of common stock on March 19, 2026, under a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, executed pre-planned option exercises and corresponding stock sales totaling 10,699 shares on March 5, 2026, under a 10b5-1 trading plan.